๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery โ—† GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons โ—† Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing โ—† Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines โ—† Trumpโ€™s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery โ—† GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons โ—† Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing โ—† Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines โ—† Trumpโ€™s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications โ—†
Updated 12 Aug 2026 ยท ClinicalTrials.gov

Clinical Trials in Bangalore

โ† All India trials

Every active and recruiting clinical study with an investigative site in India โ€” searchable by condition, sponsor, phase and location. Refreshed daily from the ClinicalTrials.gov registry.

7
Recruiting now
11
Active studies
Recruiting Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Daiichi Sankyo ยท started 2025-10-24
๐Ÿ“ Bangalore ยท Bhubaneswar ยท Howrah ยท Mangalore ยท Pune ยท Surat
NCT06899126 on ClinicalTrials.gov โ†—
Recruiting Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative
Janssen Research & Development, LLC ยท started 2025-10-01
๐Ÿ“ Bangalore ยท Bengaluru ยท Bhubaneswar ยท Ernฤkulam ยท Gurugram ยท Hyderabad
NCT07196748 on ClinicalTrials.gov โ†—
Recruiting
Capella Scientia Development Study
Cataract
Alcon Research ยท started 2025-07-30
๐Ÿ“ Bangalore
NCT06987474 on ClinicalTrials.gov โ†—
Recruiting Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Sickle Cell Disease, Thalassemia
Novo Nordisk A/S ยท started 2025-01-10
๐Ÿ“ Raipur ยท Mumbai ยท Bangalore ยท Gujarat ยท Maharashtra ยท New Delhi
NCT06609226 on ClinicalTrials.gov โ†—
Recruiting Phase 2/Phase 3
Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.
Diabetic Neuropathy Peripheral
St. John's Research Institute ยท started 2024-11-15
๐Ÿ“ Bangalore
NCT06201611 on ClinicalTrials.gov โ†—
Recruiting
Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease
Coronary Artery Disease Left Main, Coronary Artery Disease
Seung-Jung Park ยท started 2024-04-25
๐Ÿ“ Bangalore
NCT05829889 on ClinicalTrials.gov โ†—
Active Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Lupus Nephritis
Novartis Pharmaceuticals ยท started 2022-07-14
๐Ÿ“ Bangalore ยท Secunderabad ยท Lucknow ยท Chandigarh
NCT05126277 on ClinicalTrials.gov โ†—
Active Phase 1
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Advanced Solid Tumor, Lymphoma
Glenmark Specialty S.A. ยท started 2022-06-28
๐Ÿ“ Vijayawada ยท Visakhapatnam ยท Gurgaon ยท Bangalore ยท Bengaluru ยท Kannur
NCT05878691 on ClinicalTrials.gov โ†—
Active Phase 3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company ยท started 2021-10-04
๐Ÿ“ Bangalore ยท Thiruvananthapuram ยท Mumbai ยท Nagpur ยท Nashik ยท Pune
NCT04975308 on ClinicalTrials.gov โ†—
Recruiting Phase 4
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, Inflammation
Novartis Pharmaceuticals ยท started 2020-12-22
๐Ÿ“ Surat ยท Bangalore ยท Mumbai ยท Nashik ยท Hyderabad ยท New Delhi
NCT04638647 on ClinicalTrials.gov โ†—
Active Phase 2
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Carcinoma
AstraZeneca ยท started 2019-01-09
๐Ÿ“ Bangalore ยท Chennai ยท Kolkata ยท New Delhi
NCT03778229 on ClinicalTrials.gov โ†—
No trials match your search.

Browse by location

New Delhi ยท 21 Mumbai ยท 18 Hyderabad ยท 16 Bangalore ยท 11 Pune ยท 10 Chandigarh ยท 10 Ahmedabad ยท 10 Kolkata ยท 7 Jaipur ยท 7 Surat ยท 7 Bengaluru ยท 6 Lucknow ยท 6

Browse by condition

Breast Cancer ยท 3 Lupus Nephritis ยท 2 Cervical Cancer ยท 2 Hepatic Encephalopathy ยท 2 Periodontitis ยท 2
Cite this page

Priya Life Science (2026). Clinical Trials in India Tracker. Available at: https://priyalifescience.com/clinical-trials-india/city/bangalore (Accessed: 12 August 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine โ€” studies listing at least one Indian site, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician.